Colorectal Cancer: What You Need to Know
Moffitt expert highlights when and how to screen, risk factors and more
Moffitt expert highlights when and how to screen, risk factors and more
Dr. Parker and colleagues report in the current issue of Annals of Oncology the updated results of the RADICALS-RT randomized trial evaluating the superiority of…
In this episode “ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children’s Research Hospital, dive into the pioneering realm of…
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
The OncoAlert Newsletter is now out for June 23-29, 2023
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja…
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs…